Dr. Toni Choueiri on Cabozantinib Versus Everolimus in Renal Cell Carcinoma

Toni K. Choueiri, MD
Published: Sunday, Sep 27, 2015



Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Senior Physician at Dana-Farber Cancer Institute, discusses the results of the phase III METEOR trial that assessed cabozantinib for patients with advanced renal cell carcinoma (RCC).

The open-label phase III trial looked at cabozantinib, which inhibits multiple tyrosine kinases, including MET, VEGFRs, and AXL, compared with everolimus, a current standard of care, in 658 pretreated patients with RCC. Cabozantinib was investigated because VEGFR-resistance is common in RCC, making a novel VEGFR-inhibitor an unmet need, says Choueiri.

The primary endpoint of the trial was progression-free survival (PFS). The study found a 42% reduction in the risk of death or progression with cabozantinib compared to everolimus. The estimated median PFS among the first 375 randomized patients was 7.4 months with cabozantinib compared with 3.8 months for patients receiving everolimus (HR, 0.58; 95% CI, 0.45-0.75; P <.001).

<<< View more from the 2015 European Cancer Congress



Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Senior Physician at Dana-Farber Cancer Institute, discusses the results of the phase III METEOR trial that assessed cabozantinib for patients with advanced renal cell carcinoma (RCC).

The open-label phase III trial looked at cabozantinib, which inhibits multiple tyrosine kinases, including MET, VEGFRs, and AXL, compared with everolimus, a current standard of care, in 658 pretreated patients with RCC. Cabozantinib was investigated because VEGFR-resistance is common in RCC, making a novel VEGFR-inhibitor an unmet need, says Choueiri.

The primary endpoint of the trial was progression-free survival (PFS). The study found a 42% reduction in the risk of death or progression with cabozantinib compared to everolimus. The estimated median PFS among the first 375 randomized patients was 7.4 months with cabozantinib compared with 3.8 months for patients receiving everolimus (HR, 0.58; 95% CI, 0.45-0.75; P <.001).

<<< View more from the 2015 European Cancer Congress




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x